Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 25. Click on ID to see further detail.
IDOV_1446 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | AssayXTT assay | In-vitro virus concentrationLog10 pfu/cell | In-vitro result70% cell survived 48 hours after post infection | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1458 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with palcitaxel (>100 micromolar, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell death occurs at 0.069 CI value | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1464 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with palcitaxel (>100 micromolar, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% cell death at CI value 0.092 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1470 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with palcitaxel (>100 micromolar, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell death at CI value 0.133 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1476 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with palcitaxel (>100 micromolar, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell death occurs at 0.078 CI value | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1482 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with palcitaxel (>100 micromolar, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% cell death at CI value 0.081 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1488 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with palcitaxel (>100 micromolar, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell death at CI value 0.084 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1494 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with cisplatin (>100, ratio is 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1500 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with cisplatin (>100, ratio is 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1506 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with cisplatin (>100, ratio is 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1512 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with cisplatin (>100, ratio is 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1518 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with cisplatin (>100, ratio is 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1524 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with cisplatin (>100, ratio is 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1530 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Gemcitabine (>100, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell death at CI value >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1536 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Gemcitabine (>100, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75 % cell death at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1542 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Gemcitabine (>100, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1548 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Gemcitabine (>100, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1554 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Gemcitabine (>100, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1560 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus in combination with Gemcitabine (>100, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1566 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with vinblastine(>100, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1572 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with vinblastine(>100, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1578 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with vinblastine(>100, 1:20) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1584 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with vinblastine(>100, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result50% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1590 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with vinblastine(>100, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result75% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |
IDOV_1596 | Virus nameReovirus | Virus strainReoT3D | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationNone | Virus aloneNo | Virus in combination with drug/radiationVirus combination with vinblastine(>100, 1:200) | Immune gene insertion in viral genomeNo | Source of cell lineNCI | Origin of cell lineHuman NSCLC cell line | Cell lineH322M | Concentration of cell lineNA | In-vitro toxicityNA | Assaychou-Talay analysis | In-vitro virus concentrationLog10 pfu/cell | In-vitro result90% cell killing at CI >10 | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis, activation of caspase 3 | Immunogenic effectNA | Clinical trialNA | PMID19594950 |